Results 121 to 130 of about 200,281 (336)

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source

Needs of amyloidosis patients and their care providers: design & first results of the  AMY-NEEDS research and care program

Orphanet Journal of Rare Diseases
Background Amyloidosis represents a rare yet heterogeneous multi-system disorder associated with a grave prognosis and an enormous psycho-emotional strain on patients, relatives, and caregivers.
Sandra Michaela Ihne-Schubert, Teresa Radovic, Saskia Fries, Stefan Frantz, Hermann Einsele, Stefan Störk, Silke Neuderth   +6 more
doaj   +1 more source

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D.J. Capelle, Chiara Arzilli, Emiliano Fiori, Nicolò Capra, Christina Kronberger, Nikita Ermolaev, Andreas Kammerlander, Beatrice Musumeci, Giuseppe Vergaro, Vincenzo Castiglione, René Rettl, Giacomo Tini, Andrea Baggiano, Iacopo Fabiani, Susanna Sciomer, Roza Badr Eslam, Piergiuseppe Agostoni   +25 more
wiley   +1 more source

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis [PDF]

, 2016
Amyloid light-chain (LC) amyloidosis (AL amyloidosis) is a rare and fatal disease for which there are no approved therapies. In patients with AL amyloidosis, LC aggregates progressively accumulate in organs, resulting in organ failure that is ...
Ando, Y, Comenzo, RL, Dispenzieri, A, Gertz, MA, Grogan, M, Lousada, I, Maurer, MS, Merlini, G, Palladini, G, Sanchorawala, V, Wechalekar, A   +10 more
core   +1 more source

Epidemiology of AL amyloidosis: a real-world study using US claims data.

Blood Advances, 2018
Amyloid light-chain (AL) amyloidosis is a rare disease caused by extracellular deposition of misfolded immunoglobulin light chains. This study aimed to provide an up-to-date estimate of prevalence and incidence of AL amyloidosis in the United States ...
T. Quock, T. Yan, E. Chang, S. Guthrie, M. Broder   +4 more
semanticscholar   +1 more source

Hyposplenism in gastro-intestinal disease [PDF]

, 1994
The hazards of living without a spleen were recognised by the paediatricians in the early 1960’s when they focussed attention on the syndrome of fulminant sepsis, often due to pneumococcal infection, occurring in young children within the first two years
Muller, Andre F., Toghill, P. J.
core   +1 more source

Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials

ESC Heart Failure, EarlyView.
This systematic review identified 24 clinical trials of medical device and surgical interventions for HFpEF, with 16 demonstrating at least safety and feasibility, but little evidence of long‐term benefit. Phenotype‐based responses suggest that certain interventions may benefit specific HFpEF subgroups, yet most trials suffered from heterogeneous ...
Kurdo Araz, Francesco Fioretti, Sara Ladak, Mohammed Obaidan, Javed Butler, Aamir Hameed   +5 more
wiley   +1 more source

The lung in amyloidosis

European Respiratory Review, 2017
Amyloidosis is a disorder caused by misfolding of autologous protein and its extracellular deposition as fibrils, resulting in vital organ dysfunction and eventually death. Pulmonary amyloidosis may be localised or part of systemic amyloidosis. Pulmonary
Paolo Milani, Marco Basset, Francesca Russo, Andrea Foli, Giovanni Palladini, Giampaolo Merlini   +5 more
doaj   +1 more source

A new therapy for transthyretin amyloidosis, no longer an orphan condition [PDF]

, 2020
Candida Cristina Quarta, Anna Laura Tinuper, Agnese Milandri, Christian Gagliardi, Giuseppe Caponeti, Claudio Rapezzi   +5 more
openalex   +1 more source

P.041 Characteristics of carpal tunnel syndrome in wild-type transthyretin amyloidosis [PDF]

, 2022
A Russell, S Khayambashi, NM Fine, S Chhibber, C Hahn   +4 more
openalex   +1 more source